絞り込み

16533

広告

映画「007」の次回作監督は日系アメリカ人 (NHK)

世界的に人気のスパイ映画「007」シリーズの次回作の監督に、日系アメリカ人のキャリー・フクナガさんが選ばれました。 「007」シリーズの25作目の監督に選ばれた...

  1. [企業] 武田 Molecular Te...
  2. 匿名化サービス悪用、追跡困難か Zaif...
  3. [企業] 全身投与で病変のみに作用する治...
  4. G7、海のプラごみ対策議論 (デイリース...

ニュース一覧

[Laboratory aspects of novel oral anticoagulant treatment].

著者 Bereczky Z , Oláh Z , Ajzner É , Kappelmayer J
Orv Hetil.2017 Dec ; 158(49):1930-1945.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (63view , 0users)

Full Text Sources

Medical

Miscellaneous

The introduction of novel oral anticoagulants (NOAC) have long been expected drugs and they quickly became used widespread as their clinical effectiveness was as good as, or even better than the previously used only oral anticoagulant drug, the coumarins. Thus, the direct thrombin inhibitor dabigatran and the activated factor X inhibitors (rivaroxaban, apixaban, edoxaban) have become the part of daily therapeutic practice. Their permeation was facilitated by the guideline which suggested that no laboratory monitoring was required during NOAC treatment and this was very convenient for both patients and doctors. The clinical experience obtained in the past years, however have proved that the 'one size fits all' view is oversimplified and there are numerous situations when the determination NOAC levels is unavoidable or highly recommended. This review discusses the laboratory aspects of NOAC treatment, primarily summarizing their effect on the screening tests and special assays of hemostasis and we also describe the correct methods to determine their plasma concentrations. Orv Hetil. 2017; 158(49): 1930-1945.
PMID: 29199435 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード